The company said it filed the IPR challenge with the US Patent Trial and Appeal Board for US Patent No. 9,610,430 owned by Renovacare.
“We believe we have presented a very strong rationale to the PTAB as to why this patent should never have been issued, and thus, we respectfully request that all claims in the ‘430 patent should be cancelled. Avita is a pioneer in the regenerative medicine arena, and we are very protective of our intellectual property rights,” Avita CEO Adam Kelliher said in a press release.
Avita Medical has not yet said what the patent it has filed the petition against is related to.
Last month, Avita Medical saw shares jump as much as 7% after the FDA approved an expansion to the number of patients that can be treated in a trial of its ReCell regenerative device.
The ReCell device is designed to use the patient’s own skin cells to treat a variety of skin issues, including burns, reconstructive and cosmetic procedures, the company said.